Bausch Health Companies Inc. Q2 2025 Earnings Recap

BHC Q2 2025 August 1, 2025

Get alerts when BHC reports next quarter

Bausch Health reported robust performance in Q2 2025, achieving 5% revenue growth and a notable 10% increase in adjusted EBITDA, marking the ninth consecutive quarter of growth.

Earnings Per Share Miss

$0.90 vs $0.97 est.

-7.2% surprise

Revenue Miss

2530000000 vs 2583380000 est.

-2.1% surprise

Market Reaction

1-Day +1.23%

5-Day +0.7%

30-Day +28.72%

See BHC alongside your other holdings

Add to your portfolio — free

Key Takeaways

Continued strong growth in Salix and Solta segments, contributing to double-digit revenue and EBITDA increases.
The completion of a $7.9 billion debt refinancing improves capital structure and extends maturities, enabling strategic flexibility.
Acquisition agreement for DURECT Corporation aims to leverage expertise in hepatology for alcohol hepatitis treatment development.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit BHC on AllInvestView.

Next Q3 2025